One-Two Punch of Drugs Better Than Either Alone Against Colorectal Cancer
November 25, 2014 · Comments Off
CU lab study and clinical trial target two of the most commonly mutated gene signaling pathways in cancer, at the same time.
Milk Thistle Extract, Silibinin, Reduces Self-Renewal of Colorectal Cancer Stem Cells
April 7, 2014 · Comments Off
A University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 shows that the chemical silibinin, purified from milk thistle extract, affects cell signaling associated with inflammation and thus also the formation and survival of colorectal cancer stem cells.
Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
December 17, 2013 · Comments Off
Study shows that shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
October 28, 2013 · Comments Off
A University of Colorado Cancer Center study published in the journal PLoS One shows that, like overflowing a dam, colorectal cancer may resist the drug bevacizumab (Avastin), by switching dependence from the main flow of VEGF-A to the "tributaries" of related growth factors including VEGF-C, VEGF-D and placental growth factor.
CU Cancer Center Study: Young patients with metastatic colorectal cancer at higher risk
September 30, 2013 · Comments Off
AURORA, Colo. – Younger patients with colorectal cancer that has spread to other parts of...
Wait times up 78 percent at VA for colorectal cancer procedures
August 26, 2013 · Comments Off
A study published in the August print issue of the Journal of Oncology Practice shows that from 1998-2008, wait times for colorectal cancer operations at Veterans Administration hospitals increased from 19 to 32 days. But researchers think longer waits may be a reflection of several unmeasured variables including more careful care, staffing, and patient conditions or preferences.
AACR News: XL-184 (Cabozantinib) goes 12-for-12 in colorectal cancer explants
April 8, 2013 · Comments Off
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013.
Study revises colorectal cancer risk down and other cancer risks up for women with Lynch Syndrome
February 26, 2013 · Comments Off
A cooperative study that included the University of Colorado Cancer Center, published in this month's issue of the Journal of the National Cancer Institute, revises the risk of colorectal cancer down but other cancers up for women with Lynch Syndrome who have had endometrial cancer.
A diet of resistant starch helps the body resist colorectal cancer
February 19, 2013 · Comments Off
A University of Colorado Cancer Center review published in this month's issue of the journal Current Opinion in Gastroenterology shows that resistant starch helps the body resist colorectal cancer through mechanisms including killing pre-cancerous cells and reducing inflammation that can otherwise promote cancer.
Bitter melon juice prevents pancreatic cancer in mouse models
February 19, 2013
NTRK1: a new oncogene and target in lung cancer
February 19, 2013
New Program Connects Patients and Survivors at CU Cancer Center
January 26, 2015 · No comments
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith